Bristol-Myers Squibb is continuing to set precedents in China with Opdivo, the first PD-1/L1 checkpoint approved in the country, as it reportedly prices the drug at around $84,000 per year — about half of its list price in the US.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,